

## Datasheet: PIP013 BATCH NUMBER 169213

Description:	NATIVE MEASLES VIRUS
Name:	MEASLES VIRUS
Format:	Inactivated Pathogen
Product Type:	Antigen
Quantity:	1 ml

## **Product Details**

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .				
		Yes	Νο	Not Determined	Suggested Dilution
	ELISA	•			
	Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.				
Target Species	Viral				
Product Form	Inactivated Measles virus - liquid				
Preparation	Measles virus, Edmonston strain, cultured in Vero cells. Optimally infected cells are disrupted in culture fluids. The suspension is clarified and concentrated by crossflow ultrafiltration. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material.				
Buffer Solution	Minimum Essential Medium				
Preservative Stabilisers	None present				
Approx. Protein Concentrations	Current, batch-specific co	oncentratio	on 2.3 mg	ı/ml	
Product Information	Native Measles Virus pr components. The prepara culture medium.	-		-	

	The Measles virus is a highly contagious single-stranded RNA virus that is mostly spread via the respiratory system. It may be passed via aerosol droplets from coughs or through contact with infected bodily fluids. It causes measles, a disease characterised by fever, cough, runny nose, red eyes and a rash. Most patients with uncomplicated measles will recover without antiviral treatment, however, some patients may develop diarrhoea, corneal ulceration, pneumonia or encephalitis. Complications are more likely in adults. In developed countries, most children are immunised against measles by the age of 18 months, as part of the three-part MMR (measles, mumps and rubella) vaccine.					
Activity	Antigenic activity is 104% of internal reference standard.					
Instructions For Use	PIP013 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.					
References	<ol> <li>Bhoj, V.G. <i>et al.</i> (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. <u>Blood. 128 (3): 360-70.</u></li> <li>Böröcz, K. <i>et al.</i> (2022) Dynamic Features of Herd Immunity: Similarities in Age-Specific Anti-Measles Seroprevalence Data between Two Countries of Different Epidemiological History. <u>J Clin Med. 11(4):1145.</u></li> <li>Szinger, D. <i>et al.</i> (2024) Raising Epidemiological Awareness: Assessment of Measles/MMR Susceptibility in Highly Vaccinated Clusters within the Hungarian and Croatian Population—A Sero-Surveillance Analysis <u>Vaccines. 12 (5): 486.</u></li> </ol>					
Storage	Store at -70 <sup>o</sup> C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.					
Guarantee	12 months from date of despatch					
Health And Safety Information	ety       Material Safety Datasheet documentation #10286 available at: <u>https://www.bio-rad-antibodies.com/SDS/PIP013</u> 10286         This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately.					
Regulatory	For research purposes only					
Printed on 07 Nov 2024						

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint